Greenwich LifeSciences (GLSI) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Greenwich LifeSciences (GLSI) over the past year, gaining 53.0% versus a gain of 32.3%. Over five years, GLSI leads with a -60.1% price change compared with -96.6% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($257.6 million vs $233.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | ZNTL |
|---|---|---|
| Share price | $15.88 | $2.63 |
| Market cap | $233.09M | $257.57M |
| 1-day change | +4.89% | +4.58% |
| YTD return | -27.94% | +85.93% |
| 1-year return | +32.28% | +53.05% |
| 5-year return | -60.12% | -96.65% |
| EPS (TTM) | $-1.53 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $6.95 |
| 52-week low | $7.78 | $1.21 |
| Distance from 52-week high | -53.43% | -62.23% |
| Analyst consensus | none | buy |
| Avg. price target upside | +258.94% | +179.24% |
| Average volume | 138.91K | 1.21M |
| Shares outstanding | 14.68M | 98.12M |
| Employees | — | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed GLSI by 20.8 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
GLSI vs ZNTL FAQ
Which is bigger, Greenwich LifeSciences or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $257.57M compared with $233.09M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with +32.28% for GLSI (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.